The challenges and opportunities

Imaging in CNS Drug Discovery and Development: Implications for Disease and Therapy

Volumn , Issue , 2009, Pages 3-9

  Borsook, David ^a   Bullmore, Edward ^b   Becerra, Lino ^a   Hargreaves, Richard ^c  

^a MCLEAN HOSPITAL   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882144896     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0134-7_1     Document Type: Chapter

References (17)

1. Beckmann N, Mueggler T, Allegrini PR, Laurent D, Rudin M (2001) From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat Rec 265:85-100
2. Beckmann N, Kneuer R, Gremlich HU, Karmouty-Quintana H, Ble FX, Muller M (2007) In vivo mouse imaging and spectroscopy in drug discovery. NMR Biomed 20:154-185
3. Borsook D, Ploghaus A, Becerra L (2002) Utilizing brain imaging for analgesic drug development. Curr Opin Investig Drugs 3:1342-1347
4. Borsook D, Becerra L, Hargreaves R (2006) A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 5:411-424
5. CNS Market Trends, 2007 to 2010: Key Market Forecasts and Growth Opportunities. 2007 Urch Publishing
6. Collins SD (2007) Discontinued drugs in 2006: central and peripheral nervous system drugs. Expert Opin Investig Drugs 16:1743-1751
7. Elmquist JK, Flier JS (2004) Neuroscience. The fat-brain axis enters a new dimension. Science 304:63-64
8. Gomez-Mancilla B, Marrer E, Kehren J, Kinnunen A, Imbert G, Hillebrand R, Bergstrom M, Schmidt ME (2005) Central nervous system drug development: an integrative biomarker approach toward individualized medicine. NeuroRx 2:683-695
9. Hurko O, Ryan JI (2005) Translational research in central nervous system drug discovery. NeuroRx 2:671-682
10. Macdonald BK, Cockerell OC, Sander JW, Shorvon SD (2000) The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123(4):665-676
11. Matthews PM, Honey GD Bullmore ET (2006) Applications of fMRI in translational medicine and clinical practice. Nat Rev Neurosci 7:732-744
12. Obici S, Zhang BB, Karkanias G, Rossetti L (2002) Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376-1382
13. Palmer AM, Stephenson FA (2005) CNS drug discovery: challenges and solutions. Drug News Perspect 18:51-57
14. Rudin M, Allegrini MT, PR BD, Rausch M (2003) Characterization of CNS disorders and evaluation of therapy using structural and functional MRI. Anal Bioanal Chem 377:973-981
15. Silva MD, Chandra S (2006) MRI in preclinical drug development. Methods Mol Med 124:299-322
16. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, Castaneda TR, Muzzin P, Schurmann A, Szanto I, Tschop MH, Rohner-Jeanrenaud F (2006) Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116:1983-1993
17. Wise RG, Tracey I (2006) The role of fMRI in drug discovery. J Magn Reson Imaging 23:862-876